-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Aquestive Therapeutics (NASDAQ:AQST) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in. This saw it comparing AQST-109 to EpiPen in terms of effectiveness and speed of reaction.
Using a 0.3mg dose, AQST-109 achieved a time to maximum concentration (Tmax) of 12 minutes. To put that in perspective, the Tmax for EpiPen at the same dose level is 22.5 minutes. Also, the Tmax for epinephrine injection is 45 minutes.
What's Next for AQST?
Daniel Barber, CEO of Aquestive Therapeutics, said the following about what the clinical trial results mean for the company.
"We are pleased to see that AQST-109 compared favorably to both the EpiPen and the epi 0.3mg IM injection across several measures. We believe AQST-109 will provide a meaningful addition to treating anaphylaxis and we look forward to sharing the full dataset with the FDA, which will be the basis for our end-of-Phase 2 meeting scheduled for the fourth quarter of 2022."
The positive clinical trial news has AQST stock seeing heavy trading this morning. This has roughly 10 million shares on the move as of this writing. That's quite the increase over its daily average trading volume of 669,000 shares.
AQST stock is up 4% as of Tuesday morning.
Investors seeking out more of the latest stock market news are in luck!
InvestorPlace has all of the hottest stock market coverage for Tuesday! Among that is what has shares of AMC Entertainment (NYSE:AMC) moving, this morning's biggest pre-market stock movers, and more. You can read up on all of that news at the following links!
More Tuesday Stock Market News
- APE, AMC Stock Rebound After Share Sale Plunge
- Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Coinbase Suffers New, $350M Legal Threat
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市場新聞、股票建議和交易提示
Aquestive Therapeutics (NASDAQ:AQST) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
成癮治療學納斯達克(Sequoia Capital：AQST)股價週二上漲，投資者對這家制藥公司積極的臨牀試驗數據做出反應。
Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in. This saw it comparing AQST-109 to EpiPen in terms of effectiveness and speed of reaction.
Aqutive Treeutics正在開發一種可與EpiPen競爭的產品，其第二階段臨牀試驗的結果已公佈。這讓它在有效性和反應速度方面將AQST-109與EpiPen進行了比較。
Using a 0.3mg dose, AQST-109 achieved a time to maximum concentration (Tmax) of 12 minutes. To put that in perspective, the Tmax for EpiPen at the same dose level is 22.5 minutes. Also, the Tmax for epinephrine injection is 45 minutes.
在0.3 mg劑量下，AQST-109達到最大濃度的時間(Tmax)為12分鐘。客觀地説，在相同劑量水平下，EpiPen的Tmax為22.5分鐘。此外，注射腎上腺素的Tmax為45分鐘。
What's Next for AQST?
AQST的下一步是什麼？
Daniel Barber, CEO of Aquestive Therapeutics, said the following about what the clinical trial results mean for the company.
艾奎特治療公司首席執行官Daniel·巴伯在談到臨牀試驗結果對公司意味着什麼時説。
"We are pleased to see that AQST-109 compared favorably to both the EpiPen and the epi 0.3mg IM injection across several measures. We believe AQST-109 will provide a meaningful addition to treating anaphylaxis and we look forward to sharing the full dataset with the FDA, which will be the basis for our end-of-Phase 2 meeting scheduled for the fourth quarter of 2022."
我們很高興看到AQST-109在幾個指標上都比EpiPen和EPI 0.3 mg肌注更有利。我們相信AQST-109將為治療過敏反應提供一個有意義的補充，我們期待着與FDA分享完整的數據集，這將成為我們定於2022年第四季度舉行的第二階段結束會議的基礎。
The positive clinical trial news has AQST stock seeing heavy trading this morning. This has roughly 10 million shares on the move as of this writing. That's quite the increase over its daily average trading volume of 669,000 shares.
積極的臨牀試驗消息使AQST股票今天上午出現了大量交易。截至撰寫本文時，該公司約有1,000萬股在售。與其66.9萬股的日均成交量相比，這是相當大的增幅。
AQST stock is up 4% as of Tuesday morning.
截至週二上午，AQST股價上漲了4%。
Investors seeking out more of the latest stock market news are in luck!
尋求更多最新股市消息的投資者走運了！
InvestorPlace has all of the hottest stock market coverage for Tuesday! Among that is what has shares of AMC Entertainment (NYSE:AMC) moving, this morning's biggest pre-market stock movers, and more. You can read up on all of that news at the following links!
投資商位置擁有周二最熱門的股市報道！其中包括擁有的股份AMC娛樂公司(紐約證券交易所代碼：AMC)Moving，今天上午最大的盤前股票走勢，以及更多。你可以在下面的鏈接上閲讀所有的新聞！
More Tuesday Stock Market News
更多週二股市新聞
- APE, AMC Stock Rebound After Share Sale Plunge
- Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Coinbase Suffers New, $350M Legal Threat
- APE，AMC股票在股票銷售暴跌後反彈
- 今日最大的盤前炒股：週二10大漲跌股
- Coinbase遭遇新的3.5億美元法律威脅
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版日期，威廉·懷特沒有(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點，以InvestorPlace.com為準出版指南.
The post Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival appeared first on InvestorPlace.
AQST後，EpiPen競爭對手的積極數據帶來的股票收益首先出現在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧